- Record: found
- Abstract: not found
- Article: not found
Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas
Alexandros Papachristodoulou ,
Manuela Silginer ,
Michael Weller ,
Hannah Schneider ,
Kathy Hasenbach ,
Michel Janicot ,
Patrick Roth
December 02 2019
September 17 2019
Read this article at
ScienceOpenPublisherPubMed
- open (via free pdf)
- oa repository (via OAI-PMH doi match)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
Powered by 
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d18214037e122">Transforming growth factor (TGF)-β is expressed
at high levels by glioma cells and
contributes to the malignant phenotype of glioblastoma. However, its therapeutic targeting
remains challenging. Here, we examined an alternative therapeutic approach of TGFβ
inhibition using two novel phosphorothioate-locked nucleic acid (LNA)-modified antisense
oligonucleotide gapmers, ISTH1047 and ISTH0047, which specifically target TGFβ1 and
TGFβ2.
</p>